Bomedemstat

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Acute Myeloid LeukemiaSmall Cell Lung CancerMyelofibrosisPolycythemia VeraEssential Thrombocythemia

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

1

Peony

Takeda

Phase 3

62

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

13

Dalalone

CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Phase 3

14

Campath

GGenzyme, a Sanofi Company

Phase 3

—5

Caspofungin Acetate

Merck & Co.

Phase 3

16

AG-120

Institut de Recherches Internationales Servier

Phase 3

47

Salvage Chemotherapy

Daiichi Sankyo

Phase 3

18

Bomedemstat

Merck & Co.

Phase 3

19

Homoharringtonine

Ascentage Pharma Group Inc.

Phase 3

110

Consolidation Chemotherapy

SShenzhen People's Hospital

Phase 3

1Show 18 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Myelofibrosis3 trials

Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis

Unknown status·TThe University of Hong Kong·Phase 2·NCT05569538·40 enrolled

Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis

Not yet recruiting·—·Phase 2·NCT07424950·40 enrolled

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Completed·Merck & Co.·Phase 1/2·NCT03136185·90 enrolled

Essential Thrombocythemia3 trials

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Completed·Merck & Co.·Phase 2·NCT04254978·73 enrolled

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants

Recruiting·Merck & Co.·Phase 3·NCT06456346·300 enrolled

A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea

Active, not recruiting·Merck & Co.·Phase 3·NCT06079879·340 enrolled

Acute Myeloid Leukemia1 trial

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting·—·Phase 1·NCT05597306·18 enrolled

Safety and Efficacy1 trial

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Recruiting·Merck & Co.·Phase 3·NCT06351631·400 enrolled

Myeloproliferative Neoplasms1 trial

An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

Completed·Merck & Co.·Phase 2·NCT05223920·81 enrolled

5 more indications

Moderate Hepatic Impairment1 trial

A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)

Completed·Merck & Co.·Phase 1·NCT07049939·9 enrolled

Small Cell Lung Cancer1 trial

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Terminated·UUniversity of Washington·Phase 1/2·NCT05191797·3 enrolled

Polycythemia Vera1 trial

A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)

Completed·Merck & Co.·Phase 2·NCT05558696·20 enrolled

Myeloid Malignancies1 trial

A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)

Completed·Merck & Co.·Phase 1/2·NCT02842827·45 enrolled

Interaction1 trial

Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)

Completed·Merck & Co.·Phase 1·NCT06596668·16 enrolled

Details

Drug Info

Related News